Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
XB-ART-2447
J Neurosci 2005 Jan 19;253:732-6. doi: 10.1523/JNEUROSCI.4065-04.2005.
Show Gene links Show Anatomy links

A uniquely selective inhibitor of the mammalian fetal neuromuscular nicotinic acetylcholine receptor.

Teichert RW , Rivier J , Torres J , Dykert J , Miller C , Olivera BM .


???displayArticle.abstract???
We have purified and characterized a novel conotoxin from the venom of Conus obscurus, which has the unique property of selectively and potently inhibiting the fetal form of the mammalian neuromuscular nicotinic acetylcholine receptor (nAChR) (alpha1beta1gammadelta-subunits). Although this conotoxin, alphaA-conotoxin OIVB (alphaA-OIVB), is a high-affinity antagonist (IC50 of 56 nm) of the fetal muscle nAChR, it has >1800-fold lower affinity for the adult muscle nAChR (alpha1beta1epsilondelta-subunits) and virtually no inhibitory activity at a high concentration on various neuronal nAChRs (IC50 > 100 microm in all cases). The peptide (amino acid sequence, CCGVONAACPOCVCNKTCG), with three disulfide bonds, has been chemically synthesized in a biologically active form. Although the neuromuscular nAChRs are perhaps the most extensively characterized of the receptors/ion channels of the nervous system, the precise physiological roles of the fetal form of the muscle nAChR are essentially unknown.alphaA-OIVB is a potentially important tool for delineating the functional roles ofalpha1beta1gammadelta receptors in normal development, as well as in various adult tissues and in pathological states. In addition to its potential as a research tool, alphaA-OIVB may have some direct biomedical applications.

???displayArticle.pubmedLink??? 15659611
???displayArticle.pmcLink??? PMC6725330
???displayArticle.link??? J Neurosci
???displayArticle.grants??? [+]


References [+] :
Blount, Molecular basis of the two nonequivalent ligand binding sites of the muscle nicotinic acetylcholine receptor. 1989, Pubmed